# A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

> **NCT02519439** · PHASE3 · TERMINATED · sponsor: **Marinus Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Drug Resistant Partial Onset Seizure

## Interventions

- **DRUG:** ganaxolone

## Key facts

- **NCT ID:** NCT02519439
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study. Due to this outcome Marinus discontinued this extension study.
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02519439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02519439, "A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT02519439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*